newsfilter
← Latest News
Earnings Call Transcripts·

Korsana Biosciences, Inc. - 1781018 - KORSANA BIOSCIENCES INC

  • Financial Performance:

    • No specific revenue, earnings, or margin data disclosed for the quarter as the company is pre-revenue.
    • Secured over $450 million in funding as of September 2029, supporting operations through 2029.
    • Focus on capital efficiency to support the Phase 1/2 clinical program for KRSA-028.
  • Guidance and Future Outlook:

    • Phase 1/2 Data: Targeting disclosure of Single Ascending Dose (SAD) healthy volunteer data (including sub-Q tolerability and CSF exposure ratios) by mid-2027.
    • Proof of Concept: Aiming to present interim Multiple Ascending Dose (MAD) data by end of 2027 or Q1 2028 to demonstrate plaque reduction trajectory.
    • Phase 3 Launch: Targeting initiation of global Phase 3 cognitive trials in 2028, pending safety characterization and dose selection from expansion cohorts.
    • Dosing Goal: Targeting a low-volume, subcutaneous monthly dosing regimen (estimated ~150mg) enabled by half-life extension, aiming for similar C-average exposure to Roche's Trontinemab but with improved safety.
  • Business Segments and Product Lines:

    • Lead Candidate: KRSA-028, a blood-brain shuttle antibody targeting Alzheimer's disease.
    • Mechanism: Combines a pyroglutamate (pGlu) selective A-beta binding antibody with a Transferrin Receptor (TFR) shuttle for enhanced blood-brain barrier penetration.
    • Engineering Features:
      • IgG backbone modified for half-life extension (specific mutations undisclosed) to enable subcutaneous delivery.
      • Retains Fc-mediated phagocytosis for plaque clearance (unlike some competitors that eliminate effector function).
      • Engineered to eliminate Complement Dependent Cytotoxicity (CDC) and Antibody-Dependent Cellular Cytotoxicity (ADCC) to reduce risks of acute reticulocyte depletion (anemia) observed with Trontinemab.
    • Development Partnership: Developed in collaboration with Paragon Laboratories.
  • Market and Competitive Landscape:

    • Market Size: Current market for symptomatic Alzheimer's therapy is expected to double if pre-symptomatic (preclinical) trials (e.g., Lilly's Trailblazer-ALZ3) validate efficacy in earlier stages.
    • Competition:
      • Roche: Trontinemab is the benchmark for TFR shuttles; Phase 3 data expected H1 2028, aiming for faster plaque clearance and reduced ARIA rates compared to first-gen drugs.
      • Biogen/Lilly: Lecanemab and Donanemab approved but require higher doses/IV administration; Denali and AbbVie are other competitors in the shuttle space.
    • Differentiation: Aims to match or exceed Trontinemab's plaque clearance speed while offering superior safety (lower ARIA and anemia risks) and convenience (subcutaneous vs. IV).
  • Risks and Challenges:

    • Safety: Primary risks include potential for ARIA (Amyloid-Related Imaging Abnormalities) and anemia; the company aims to mitigate these through lower peripheral antibody exposure and Fc engineering.
    • Clinical Execution: Reliance on achieving a CSF-to-serum ratio of 7-8x (matching Trontinemab) to validate shuttle functionality; potential delays in Phase 3 enrollment or regulatory acceptance of subcutaneous data.
    • Competitive Validation: Success of the TFR shuttle platform is contingent on Roche's upcoming Phase 3 data (expected H1 2028).
  • Management Commentary and Tone:

    • Tone: Highly confident and strategic; management views the TFR shuttle platform as the most de-risked approach to next-generation Alzheimer's therapy.
    • Philosophy: Believes that "less is more"—using a shuttle to deliver lower doses reduces peripheral crowding and immune reactions at the blood-brain barrier, thereby lowering ARIA risk.
    • Focus: Emphasizes that the company's sole focus is advancing KRSA-028, with sufficient financing to do so without near-term dilution concerns.
  • Analyst Questions and Answers:

    • Q: Efficacy vs. Trontinemab?
      • A: Management expects KRSA-028 to achieve at least equivalent plaque reduction and cognitive benefit, potentially faster onset due to pGlu epitope targeting, but primarily aims to match Trontinemab's trajectory with better safety.
    • Q: Dosing and Half-life?
      • A: Half-life extension is designed to allow lower doses and monthly subcutaneous dosing, not necessarily to extend dosing intervals beyond monthly. The target is to maintain a C-average similar to Trontinemab IV but via a safer, lower-volume SC route.
    • Q: Safety (ARIA/Anemia)?
      • A: Believes ARIA rates will be in the single digits (similar to Trontinemab's improvement over first-gen drugs) due to lower total antibody burden and diffuse brain penetration. Anemia risk is mitigated by eliminating CDC/ADCC effector functions.
    • Q: Pre-symptomatic Market?
      • A: Acknowledges the potential for a doubled Total Addressable Market (TAM) if pre-symptomatic trials prove effective; however, safety is even more critical in this healthier population where the risk of ARIA must be minimal.
  • Other Key Points:

    • Pre-clinical Data: Non-human primate studies support the 150mg monthly sub-Q dose hypothesis.
    • Clinical Design: Phase 1/2 study includes Single Ascending Dose (healthy volunteers), Multiple Ascending Dose (patients), and expansion cohorts for Phase 3 enabling safety data.
    • CSF Metrics: Success metric for the shuttle is a CSF-to-serum concentration ratio in the range of 7-8x, as demonstrated by Roche.
    • Commercialization Plan: Aims to launch with an auto-injector for at-home use to maximize patient convenience compared to IV infusions.
Company
KORSANA BIOSCIENCES INC
Keywords
KORSANA BIOSCIENCES INC